Left to Their Own Devices, Capital Markets Cannot Save the Planet
NEW YORK--(BUSINESS WIRE)--#ESG--Despite attracting a wall of money, capital markets are failing to price in…
4 years ago
Wire Stories
Mitsubishi Electric Announces Name of Subsidiary That Will Integrate Building Systems Business Following Company Split
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today the name of Mitsubishi Electric Building Techno-Service…
4 years ago
Galaxy Entertainment Group Selected Unaudited Q3 2021 Financial Data
Continue Working Closely with Macau Community to Control COVID-19 Q3 2021 Group Adjusted EBITDA of…
4 years ago
Hytera Showcases Latest Convergent Communication Innovations and Solutions at CCW 2021
SHENZHEN, China--(BUSINESS WIRE)--#CCW--Critical Communications World (CCW) brings together top professional users, operators, developers and manufacturers…
4 years ago
Samsung Announces Availability of Its Leading-Edge 2.5D Integration ‘H-Cube’ Solution for High Performance Applications
'H-Cube' applies advanced silicon interposer technology and hybrid-substrate structure, allowing efficient integration of 6 HBMs,…
4 years ago
VisualCamp Eye Tracking Software, SeeSo Named as CES 2022 Innovation Awards Honoree
SEOUL, South Korea--(BUSINESS WIRE)--#AIBasedEyeTrackingSolution--VisualCamp announced that it has been named a CES® 2022 Innovation Awards…
4 years ago
Coupang Reschedules Third Quarter 2021 Results to November 12, 2021
SEOUL, South Korea--(BUSINESS WIRE)--In recognition of the U.S. Federal Holiday, Coupang, Inc. (NYSE: CPNG) is…
4 years ago
Asia Pacific Sourcing Market Driven by Cloud Services in Q3
IaaS and SaaS demand continues to climb to record highs, but managed services growth slows…
4 years ago
Dreamstime’s Android Companion for Contributors Now Connects With Instagram and Google Photos
NASHVILLE, Tenn.--(BUSINESS WIRE)--#ThePhotoHour--Dreamstime, the world’s largest stock photo community, announces it has optimized its contributors’…
4 years ago
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
-- The EVER-132-001 trial met its primary endpoint with an objective response rate of 38.8%…
4 years ago